Terns Surges 29.6% in Three Months: Will the Momentum Continue?
TERN has outperformed the industry in the past three months on encouraging pipeline progress of its candidates. Positive data on obesity candidates should boost the stock further.
Wall Street Analysts Think Terns Pharmaceuticals (TERN) Could Surge 78.74%: Read This Before Placing a Bet
The consensus price target hints at a 78.7% upside potential for Terns Pharmaceuticals (TERN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Terns (TERN) Gains 13.6% YTD: Will the Momentum Continue?
Terns Pharmaceuticals, Inc. (TERN) outperforms the industry year to date on encouraging pipeline progress of its oncology candidate.
Wall Street Analysts Believe Terns Pharmaceuticals (TERN) Could Rally 136.44%: Here's is How to Trade
The consensus price target hints at a 136.4% upside potential for Terns Pharmaceuticals (TERN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
